Isobella Honeyborne

Dr. Isobella Honeyborne

Division of Infection and Immunity, University College London, London, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
EPEskild Petersen
Eskild Petersen
IAIbrahim Abubakar
Ibrahim Abubakar
CIChikwe Ihekweazu
Chikwe Ihekweazu
DHDavid Heymann
David Heymann
FNFrancine Ntoumi
Francine Ntoumi
AZAlimuddin Zumla
Alimuddin Zumla
The identification of monkeypox in 3 separate patients in the United Kingdom in September raised media and political attention on an emerging public health threat. Nigeria, whose last confirmed case of monkeypox was in 1978, is currently experiencing an unusually large and outbreak of human monkeypox cases, a 'One Human-Environmental-Animal Health' approach is being effectively used to define and tackle the outbreak. As of 13th October 2018, there have been one hundred and sixteen confirmed cases the majority of whom are under 40 years. Over the past 20 years ten Central and West African countries have reported monkeypox cases which have risen exponentially. We review the history and evolution of monkeypox outbreaks in Africa and USA, the changing clinical presentations, and discuss possible factors underlying the increasing numbers being detected including the cessation of smallpox vaccination programs. Major knowledge gaps remain on the epidemiology, host reservoir, and emergence, transmission, pathogenesis and prevention of monkeypoz.

1 November 2011 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
IHIsobella Honeyborne
Isobella Honeyborne
TMTimothy McHugh
Timothy McHugh
PPPatrick P. J. Phillips
Patrick P. J. Phillips
SBSelina Bannoo
Selina Bannoo
ABAnna Bateson
Anna Bateson
SGStephen H. Gillespie
Stephen H. Gillespie
A molecular assay to quantify Mycobacterium tuberculosis is described. In vitro , 98% ( n = 96) of sputum samples with a known number of bacilli (10 7 to 10 2 bacilli) could be enumerated within 0.5 log 10 . In comparison to culture, the molecular bacterial load (MBL) assay is unaffected by other microorganisms present in the sample, results are obtained more quickly (within 24 h) and are seldom inhibited (0.7% samples), and the MBL assay critically shows the same biphasic decline as observed longitudinally during treatment. As a biomarker of treatment response, the MBL assay responds rapidly, with a mean decline in bacterial load for 111 subjects of 0.99 log 10 (95% confidence interval [95% CI], 0.81 to 1.17) after 3 days of chemotherapy. There was a significant association between the rate of bacterial decline during the same 3 days and bacilli ml −1 sputum at day 0 (linear regression, P = 0.0003) and a 3.62 increased odds ratio of relapse for every 1 log 10 increase in pretreatment bacterial load (95% CI, 1.53 to 8.59).

29 May 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
Najmul HaiderNajmul Haider
Najmul Haider
JGJavier Guitian
Javier Guitian
DSDavid Simons
David Simons
DADanny Akhere Asogun
Danny Akhere Asogun
RARashid Ansumana
Rashid Ansumana
AZAlimuddin Zumla
Alimuddin Zumla
We explain research gaps on Monkeypox (MPX) virus epidemiology in endemic countries and present hypotheses for the recent increase of MPX cases in West Africa as a possible explanation for the current epidemic in Europe, America, and Australia. The detection of >400 MPX cases in less than a month in May 2022, across many countries underscores the epidemic potential of MPX in humans and demonstrates several important research gaps. First, the true burden of MPX in West and Central Africa is poorly understood, although it is critical for prevention and control of future outbreaks. Second, the diversity and extent of the animal reservoir remain unknown. We hypothesize that the synanthropic rodent population has increased in recent years in Africa leading to more human-rodent interactions and thus increased transmission of MPXV. We further hypothesise that nearly 45 years after the end of routine smallpox vaccination, the larger and more interconnected immune-naïve population has crossed a threshold resulting in more sustainable human-to-human transmission of MPXV. The current epidemic in the Western World is possibly a consequence of increased local transmission of MPXV in Africa. A new estimation of the basic and effective reproduction rate (R0 and Re) in different populations is required. National, regional, and international collaborations are needed to address research gaps related to MPX outbreaks.

1 August 2014 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
IHIsobella Honeyborne
Isobella Honeyborne
BMBariki Mtafya
Bariki Mtafya
PPPatrick P. J. Phillips
Patrick P. J. Phillips
MHMichael Hoelscher
Michael Hoelscher
ENElias N. Ntinginya
Elias N. Ntinginya
NHNorbert Heinrich
Norbert Heinrich
We evaluated the use of the molecular bacterial load (MBL) assay, for measuring viable Mycobacterium tuberculosis in sputum, in comparison with solid agar and liquid culture. The MBL assay provides early information on the rate of decline in bacterial load and has technical advantages over culture in either form.

7 April 2016 in BMC Medicine
Verified
Journal Article
Open access
PDF file
IHIsobella Honeyborne
Isobella Honeyborne
TMTimothy McHugh
Timothy McHugh
IKIitu Kuittinen
Iitu Kuittinen
ACAnna Cichonska
Anna Cichonska
DEDimitrios Evangelopoulos
Dimitrios Evangelopoulos
SWSimon Waddell
Simon Waddell
New treatment options are needed to maintain and improve therapy for tuberculosis, which caused the death of 1.5 million people in 2013 despite potential for an 86 % treatment success rate. A greater understanding of Mycobacterium tuberculosis (M.tb) bacilli that persist through drug therapy will aid drug development programs. Predictive biomarkers for treatment efficacy are also a research priority. Genome-wide transcriptional profiling was used to map the mRNA signatures of M.tb from the sputa of 15 patients before and 3, 7 and 14 days after the start of standard regimen drug treatment. The mRNA profiles of bacilli through the first 2 weeks of therapy reflected drug activity at 3 days with transcriptional signatures at days 7 and 14 consistent with reduced M.tb metabolic activity similar to the profile of pre-chemotherapy bacilli. These results suggest that a pre-existing drug-tolerant M.tb population dominates sputum before and after early drug treatment, and that the mRNA signature at day 3 marks the killing of a drug-sensitive sub-population of bacilli. Modelling patient indices of disease severity with bacterial gene expression patterns demonstrated that both microbiological and clinical parameters were reflected in the divergent M.tb responses and provided evidence that factors such as bacterial load and disease pathology influence the host-pathogen interplay and the phenotypic state of bacilli. Transcriptional signatures were also defined that predicted measures of early treatment success (rate of decline in bacterial load over 3 days, TB test positivity at 2 months, and bacterial load at 2 months). This study defines the transcriptional signature of M.tb bacilli that have been expectorated in sputum after two weeks of drug therapy, characterizing the phenotypic state of bacilli that persist through treatment. We demonstrate that variability in clinical manifestations of disease are detectable in bacterial sputa signatures, and that the changing M.tb mRNA profiles 0–2 weeks into chemotherapy predict the efficacy of treatment 6 weeks later. These observations advocate assaying dynamic bacterial phenotypes through drug therapy as biomarkers for treatment success.

1 March 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
IHIsobella Honeyborne
Isobella Honeyborne
MLMarc Lipman
Marc Lipman
AZAlimuddin Zumla
Alimuddin Zumla
TMTimothy McHugh
Timothy McHugh